Evolving Standards of Care

Posted: June 2017 For the past 40 years the International Association for the Study of Lung Cancer has remained the only society exclusively dedicated to the study and treatment of […]

Posted: April 2017 By Giorgio Vittorio Scagliotti, MD, PhD The ambition to personalize medicine is intrinsic to the mission of every individual physician with the twin goals of reducing drug-related […]

Posted: February 2017 By Cynthia L. Kryder, MS Clinical trials are essential to the development of new, potentially lifesaving therapies for patients with cancer. Well-designed clinical trials contribute to medical […]

Posted: February 2017 By Caicun Zhou, MD As part of an ongoing series, IASLC Lung Cancer News is exploring how drug approval processes differ country by country, and continent by […]

Posted: February 2017 Q&A with with Ronan J. Kelly, MB BCh, MBA Q: What is the impetus for the development of clinical pathways? A: The incidence of cancer in the US […]

Posted: February 2017 By Lori Alexander, MTPW, ELS, MWC Drug development has become a biomarker- driven process, necessitating new approaches and clinical trial designs. Speakers addressed these issues in the […]

By Sanjay Popat, FRCP, PhD United Kingdom Healthcare System The United Kingdom (UK) has a unique healthcare system: the National Health Service (NHS), a publicly funded, singlepayer system. Founded by […]

By Matteo Giaj Levra, MD, and Silvia Novello MD, PhD In September, the 2016 ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up of metastatic nonsmall cell lung cancer (NSCLC) […]

The College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) published online in April 2013 the original “Molecular Testing […]

By Erik J. MacLaren, PhD The table at right lists key updates to the National Comprehensive Cancer Network (NCCN) Guidelines for NSCLC as of February 2016. These guidelines are not […]